Coronary microvascular dysfunction

Disease2 papers

Trial sponsors

Tina Vilsbøll
1 trialPhase 4124 people
The Christ Hospital
1 trialPhase 2120 people

Funding

National Heart, Lung, and Blood InstituteUS$1.6m2 grants since 2025

Beyond BMI: Role of Body Composition, Coronary Microvascular Dysfunction and HFpEF in Characterizing Cardiometabolic Disease Phenotypes
National Heart, Lung, and Blood InstituteBrigham and Women's HospitalUS$742k2025–2030
Cardiac MRI Phenotyping of Coronary Microvascular Dysfunction
National Heart, Lung, and Blood InstituteBeth Israel Deaconess Medical CenterUS$848.1k2026–2031

Latest

8

Lipids in Health and DiseaseReview4 h

Triglyceride-glucose index as a cardiovascular risk marker: updated evidence, limitations, and future perspectives

Triglyceride-glucose index

Frontiers in Cardiovascular MedicineReviewYesterday

Coronary heart disease in young women: risk factors, mechanistic phenotypes, and implications for primary care

Arteriosclerosis, Thrombosis, and Vascular BiologyHuman trial2 Oct

Empagliflozin Improves Angina and Endothelial Dysfunction Indices in Angina and No Obstructive Coronary Arteries (ANOCA)

Current Opinion in CardiologyReview2 Sep

Beyond stenosis: imaging phenotyping and risk stratification in nonobstructive coronary artery disease

Coronary artery disease

ADA Scientific Sessions 2026 AbstractHuman trial6 Jun

Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)

AHA Scientific Sessions 2025 AbstractHumans3 Nov

Functional Capacity, Average Daily Step Count, and Angina among Women with Coronary Microvascular Dysfunction Compared to Obstructive Coronary Artery Disease and Healthy Control

AHA Scientific Sessions 2025 AbstractAnimals3 Nov

The Role of Sirtuin 6 in the Coronary Microvascular Dysfunction in Diabetes and Aging

AHA Scientific Sessions 2025 AbstractAnimals3 Nov

Low-Dose Semaglutide Attenuates Coronary Artery Pathology and Improves Vascular Function Independent of Weight Loss in a Porcine Model of Cardiometabolic HFpEF

ADA Scientific Sessions 2025 AbstractHuman trial13 Jun

The Significant Reduction in Epicardial Adipose Tissue Thickness after Dapagliflozin Treatment Is Preserved and Even Increased after Four Years—The DAPAHEART Four-Year Follow-up Study